- Home
- CYCU vs NXL Comparison
CYCU vs NXL Comparison
Compare CYCU & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | NXL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 18.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CYCU | NXL |
|---|---|---|
| Price | $2.43 | $0.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | $5.00 |
| AVG Volume (30 Days) | 147.3K | ★ 177.0K |
| Earning Date | 02-24-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,667,874.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $0.54 |
| 52 Week High | $2,028.87 | $3.87 |
Technical Indicators
Market Signals| Indicator | CYCU | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 36.27 |
| Support Level | $2.29 | $0.61 |
| Resistance Level | $2.91 | $0.77 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 17.90 | 2.06 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.